Tivozanib: current status and future directions in the treatment of solid tumors

Bibliography

• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6
   PubMed Web of Science ®Google Scholar
• Plate KH, Breier G, Millauer B, Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993;53(23):5822-7
   PubMed Web of Science ®Google Scholar
• Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995;36(2):193-204
   PubMed Web of Science ®Google Scholar
• Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995;36(2):127-37
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362(6423):841-4
   PubMed Web of Science ®Google Scholar
• Asano M, Yukita A, Matsumoto T, Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res 1995;55(22):5296-301
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
   PubMed Web of Science ®Google Scholar
• FDA Approval for Bevacizumab. Available from: http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab [Last accessed 8 August 2012]
   Google Scholar
• II, Vredenburgh JJ, Desjardins A, Herndon JE Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25(30):4722-9
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• NCT00703326: a Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer. Available from: http://www.clinicaltrials.gov [Last accessed 8 August 2012]
   Google Scholar
• NCT01170663: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine. Available from: http://www.clinicaltrials.gov [Last accessed 8 August 2012]
   Google Scholar
• NCT01140347: A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH). Available from: http://www.clinicaltrials.gov [Last accessed 8 August 2012]
   Google Scholar
• NCT01183780: A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine. Available from: http://www.clinicaltrials.gov [Last accessed 8 August 2012]
   Google Scholar
• NCT01168973: a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy. Available from: http://www.clinicaltrials.gov [Last accessed 8 August 2012]
   Google Scholar
• Demetri GD, Huang X, Garrett CR, Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):10524
   Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
   PubMed Web of Science ®Google Scholar
• Gomez-Rivera F, Santillan-Gomez AA, Younes MN, The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clin Cancer Res 2007;13(15 Pt 1):4519-27
   PubMed Web of Science ®Google Scholar
• Skolarikos AA, Papatsoris AG, Alivizatos G, Deliveliotis C. Molecular pathogenetics of renal cancer. Am J Nephrol 2006;26(3):218-31
   PubMed Web of Science ®Google Scholar
• Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22(24):4991-5004
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931-9
   PubMed Web of Science ®Google Scholar
• TIVO-1 study in renal cell carcinoma. Available from: http://www.epgonline.org/news/2012/Aug/Updated-results-of-TIVO-1.cfm [Last accessed 23 September 2012]
   Google Scholar
• Tivozanib: pubChem Compound Summary. Available from: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9911830 [Last accessed 12 August 2012]
   Google Scholar
• Nakamura K, Taguchi E, Miura T, KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 2006;66(18):9134-42
   PubMed Web of Science ®Google Scholar
• Eskens FA, de Jonge MJ, Bhargava P, Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin Cancer Res 2011;17(22):7156-63
   PubMed Web of Science ®Google Scholar
• Eskens F, Oldenhuis CN, Bhargava P, A phase Ib, open-label, dose-escalation study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors. ASCO Meeting Abstr 2011;29(4 Suppl):549
   Google Scholar
• Eskens F, Oldenhuis CN, Loos WJ, Final results of a phase Ib study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors. ASCO Meeting Abstr 2012;30(15 Suppl):4132
   Google Scholar
• NCT01478594: a Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects. Available from: http://www.clinicaltrials.gov [Last accessed 12 August 2012]
   Google Scholar
• NCT01306630: A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors. Available from: http://www.clinicaltrials.gov [Last accessed 12 August 2012]
   Google Scholar
• Mayer EL, Scheulen ME, Beckman J, Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer: results of a phase I study. ASCO Meeting Abstr 2011;29(15 Suppl):1092
   Google Scholar
• Nosov D, Bhargava P, Esteves WB, Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC). ASCO Meeting Abstr 2011;29(15 Suppl):4550
   Google Scholar
• Motzer RJ, Nosov D, Eisen T, Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. ASCO Meeting Abstr 2012;30(15 Suppl):4501
   Google Scholar
• Kabbinavar FF, Srinivas S, Hauke RJ, Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC). ASCO Meeting Abstr 2011;29(15 Suppl):4549
   Google Scholar
• Rini BI, Cohen DP, Lu DR, Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103(9):763-73
   PubMed Web of Science ®Google Scholar
• AVEO Pharmaceuticals Press Release: aveo Reports Second Quarter 2012 Financial Results. Available from: http://investor.aveopharma.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=1721417&highlight= [Last accessed 11 August 2012]
   Google Scholar
• Pfizer Press Release: Pfizer Provides Topline Results From Phase 3 Study Of Torisel® As Second-Line Treatment In Advanced Renal Cell Carcinoma (RCC). Available from: http://www.pfizer.com/news/press_releases/pfizer_press_release.jsp?guid=20120515006852en&source=RSS_2011&page=2 [Last accessed 11 August 2012]
   Google Scholar
• Halabi S, Rini BI, Stadler WM, Small EJ. Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 2010;28(15 Suppl):4525
   Google Scholar
• Montero AJ, Vogel C. Fighting fire with fire: rekindling the bevacizumab debate. N Engl J Med 2012;366(4):374-5
   PubMed Web of Science ®Google Scholar
• Robinson MO, Lin J, Feng B, Correlation of a tivozanib response biomarker identified in a preclinical model with clinical activity in a phase II study in renal cell carcinoma (RCC). ASCO Meeting Abstr 2010;28(15 Suppl):e13564
   Google Scholar
• Hutson TE, Rathmell K, Hudes GR, A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC). ASCO Meeting Abstr 2012;30(15 Suppl):TPS4686
   Google Scholar
• DePrimo S, Bello C, Smeraglia J, Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5(1):32
   PubMed Web of Science ®Google Scholar
• Ilias-Khan NA, Khakoo AY, Tannir NM. A clinical and biological profile to predict risk of development of hypertension in patients with non-clear cell renal cell carcinoma treated with sunitinib. J Clin Oncol (Meeting Abstracts) 2010;28(15 Suppl):4601
   PubMedGoogle Scholar
• Feldman DR, Baum MS, Ginsberg MS, Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(9):1432-9
   PubMed Web of Science ®Google Scholar
• Socinski MA, Scappaticci FA, Samant M, Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol 2010;5(3):354-60
   PubMed Web of Science ®Google Scholar
• Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009;7(1):24-7
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
   PubMed Web of Science ®Google Scholar